Tests how insulin affects fat breakdown in adults with obesity
Studies how insulin acts on fat tissue in adults with obesity.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Regional Lipolysis Insulin Regulation
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 48 people, planned
- Started
- 1 May 2024
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Insulin
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who are overweight or obese, with fat mostly in the upper body or mostly in the lower body.
- Age
- 18 to 65 years
- Sex
- Men and women can join.
- Disease stage
- Overweight or obesity with a BMI of 29.0 - 37.0 kg/m2. Either upper body (belly) obesity or lower body obesity, as set out by waist-hip ratio, CT scan fat measures and blood tests.
- Earlier treatment
- Cannot be taking medicines that change fat metabolism, such as niacin, thiazolidinediones, beta-blockers, corticosteroids or anabolic steroids. For 3 days before the study, all meals come from the Mayo Clinical Research Trials Unit.
- Biomarker or test result
- Waist-hip ratio, visceral fat on a CT scan, and blood fat and sugar levels are used to sort people into upper body or lower body obesity. Women of childbearing age need a negative urine pregnancy test.
Main reasons for not taking part
- Ischemic heart disease or atherosclerotic valvular disease
- Blood pressure persistently above 160/95 despite medication
- Smoking
- Diabetes mellitus
- Allergy to lidocaine or indocyanine green
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Males and females 18-65years who are able to comprehend instructions, follow study procedures and who willing to provide written, informed consent will be included. The volunteers will consume an isoenergetic diet eating all meals from Mayo Clinical Research Trials Unit (CRTU) for 3 days prior to study
- Overweight/Obese volunteers will have a BMI 29.0 - 37.0 kg/m2; Upper body/visceral obesity (UBO) in women will be defined as those with a waist-hip ratio (WHR) \> 0.85 and/or increased visceral fat by single slice CT scan, usually with \> 120 cm2 of visceral fat by CT scanning or a visceral fat/total fat ratio of \> 0.30, and/or biochemical evidence of metabolic syndrome as defined by ATP III criteria (fasting plasma triglycerides ≥ 150 mg/dL, HDL-cholesterol \< 50 mg/dL for women and \< 40 mg/dL for men, fasting plasma glucose ≥ 100 mg/dL). Upper body obesity in men will be defined as a waist-hip ratio of \>0.95 and/or increased visceral fat (visceral fat area \> 180 cm2 or a visceral/total fat abdominal ratio by CT of \> 0.40) by single slice CT scan and/or biochemical evidence of metabolic syndrome as defined by adenosine triphosphate (ATP) III criteria. These visceral fat values are based upon the data collected at Mayo Clinic using our methods, and are correlated with dyslipidemia and hyperinsulinemia; Lower body obesity (LBO) in women will be defined as a waist-hip ratio of \<0.75 and/or a lower visceral fat by single slice CT scan, usually \< 120 cm2 or a visceral fat/total fat ratio of ≤ 0.30 and fasting plasma triglycerides within the normal range. The term "lower body men" is used to describe a male phenotype that is characteristic of adipose insulin sensitivity even with excess body fat. A waist to hip ratio isn't suitable for this description as it is for women. LBO men will be defined as obese men with normal fasting plasma triglycerides, normal fasting plasma glucose and greater proportional leg fat via dual-energy x-ray absorptiometry (DEXA)
- Female subjects are eligible if they meet the following criteria:; Are not pregnant or nursing; All women of childbearing potential will have a negative urine pregnancy test at screening and a negative urine pregnancy test day of admission for inpatient study visit
Who cannot take part
- Concomitant use of medications that can alter free fatty acid metabolism, including, but not limited to niacin, thiazolidinediones, beta-blockers, oral or injected corticosteroids or anabolic steroids
- Individuals with a history of a disease process such as:; Ischemic heart disease; Atherosclerotic valvular disease; Persistent blood pressure greater than 160/95 despite antihypertensive medication
- Diagnosis Diabetes Mellitus
- Allergy to lidocaine
- Allergy to indocyanine green
- Smokers
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Madeline S ReidTaking people
About the trial
What the trial wants to find out
Adults who gain most of their excess weight in the abdominal area typically do not respond to insulin in the same way as lean adults. Researchers are trying to understand why fat tissue responds differently in people with different body types.
The 2 groups in the trial
- obesity statusOther group
obesity
Treatment: Insulin
- leanOther group
non-obese
Treatment: Insulin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Insulin Regulation of Regional Lipolysis
- Plain-language title
- Tests how insulin affects fat breakdown in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06392854, who can take part
- Record updated
- 13 April 2026